Clinical Trial Search

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: Percentage of Patients With Significant Pain Reduction — 90.3 percentage of participants

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Change in Pain Score at 60 Minutes — 4; 5 score on a scale

Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33

Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012

Primary: Number of Headache Days Per Month — 10.6; 10.9 days per month — p=0.63

Primary: Change in Pain Score — 3.8; 5.1 units on a scale

Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Number of Patients Enrolled in the Study — 24; 24 Participants

Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants

Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score

Primary: Numerical Rating Scale — 4.1; 4.3 units on a scale

Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants

Primary: Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 — 5.9; 6.2; 6.6; -0.9 Migraine attacks — p=0.1646

Primary: Number of Participants With Adequate Relief of Headache as a Measure of Efficacy — 34; 32 Participants — p=0.14

Primary: Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. — -5.67; -3.5 days — p=0.4267

Primary: Total Number of Responders — 17 Participants

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 40; 38 Participants

Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079

Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants

Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027

Primary: Change in Frequency of Migraine Days During the Last 28 Day Interval of the Treatment Period as Compared to the 28 Day Baseline Period. — 4.5 days